Hims & Hers' (NYSE: HIMS) stock crashed over 30% following news highlighting the end of its relationship with Novo Nordisk ...

Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...